2024
Biologics for Psoriasis
Wride A, Chen G, Spaulding S, Tkachenko E, Cohen J. Biologics for Psoriasis. Dermatologic Clinics 2024, 42: 339-355. PMID: 38796266, DOI: 10.1016/j.det.2024.02.001.Peer-Reviewed Original ResearchConceptsIL-23IL-17ALong-term risk-benefit profileTNF-aLong-term adverse eventsIL-23 inhibitorsTumor necrosis factor-alphaP19 subunit of IL-23Risk-benefit profileSubunit of IL-23TNF-a inhibitorsTreatment of psoriasisNecrosis factor-alphaHigher Psoriasis AreaRates of short-termIL-12/23Psoriasis AreaIL-17FAdverse eventsIL-12IL-17Factor-alphaP19 subunitInjectable biologicsP40 subunit
2023
Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis
Murphy M, Hwang E, Singh K, Lee T, Cohen J, Damsky W. Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis. British Journal Of Dermatology 2023, 190: 132-134. PMID: 37818837, DOI: 10.1093/bjd/ljad389.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedBiopsyEczemaHumansMachine LearningSkinTreatment OutcomeImmune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedHumansImmune Checkpoint InhibitorsInterleukin-13Pemphigoid, BullousConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearance
2022
Utilization, cost, and prescription patterns of dupilumab among Medicare beneficiaries in the United States from 2017 to 2019
Murphy MJ, Cheraghlou S, Damsky W, Cohen JM. Utilization, cost, and prescription patterns of dupilumab among Medicare beneficiaries in the United States from 2017 to 2019. Journal Of Dermatological Treatment 2022, 33: 3214-3215. PMID: 36137225, DOI: 10.1080/09546634.2022.2127304.Peer-Reviewed Original Research
2021
Comment on: Development of psoriasis during treatment with dupilumab: A systematic review
Cohen JM, Damsky W. Comment on: Development of psoriasis during treatment with dupilumab: A systematic review. Journal Of The American Academy Of Dermatology 2021, 86: e115. PMID: 34311044, DOI: 10.1016/j.jaad.2021.06.893.Peer-Reviewed Original ResearchDupilumab‐induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin‐17A expression: a case report
Mirza F, Wang A, Ramachandran S, Damsky W, Cohen J. Dupilumab‐induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin‐17A expression: a case report. British Journal Of Dermatology 2021, 185: 432-434. PMID: 33730377, DOI: 10.1111/bjd.20064.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedDermatitis, AtopicHumansInterleukin-17PhenotypePsoriasisConceptsInterleukin-17A expression
2020
Early Adoption of Dupilumab in the Medicare Population in 2017.
Cheraghlou S, Cohen JM. Early Adoption of Dupilumab in the Medicare Population in 2017. The Yale Journal Of Biology And Medicine 2020, 93: 675-677. PMID: 33380928, PMCID: PMC7757055.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, Monoclonal, HumanizedDermatitis, AtopicHumansMedicareRetrospective StudiesUnited StatesConceptsAtopic dermatitisRural-Urban Continuum CodesMedicare populationHealth Statistics Urban-Rural Classification SchemeInjectable biologicsSevere atopic dermatitisRetrospective cohort studyCohort studyPatient outcomesDupilumabFirst drugMedicare Provider UtilizationFDA approvalUtilization trendsFirst FDAFuture interventionsProvider UtilizationPotential targetBiologicsDisease treatmentPatientsTreatmentFirst yearMore rural regionsContinuum Codes
2018
Access to injectable biologic medications by medicare beneficiaries: geographic distribution of US dermatologist prescribers
Feng H, Cohen JM, Neimann AL. Access to injectable biologic medications by medicare beneficiaries: geographic distribution of US dermatologist prescribers. Journal Of Dermatological Treatment 2018, 30: 237-239. PMID: 30078341, DOI: 10.1080/09546634.2018.1508819.Peer-Reviewed Original Research